FDA Flags Recall of Nearly 1 Million Bottles of Heart and Kidney Medications Nationwide

The U.S. Food and Drug Administration has flagged a nationwide recall affecting approximately 944,142 bottles of two critical prescription medications used to treat chronic heart failure and kidney disease, after “unexpected foreign matter” was discovered on the surface of tablets in a reserve sample. California-based biotechnology company Amgen initiated the voluntary recall on June 4, with the FDA classifying it as Class II on June 23, 2026.

What Is Being Recalled

The recall covers 63 lots of Corlanor (ivabradine) and 3 lots of Sensipar (cinacalcet hydrochloride) that were distributed across the United States between October 28, 2021, and December 30, 2025. Corlanor is prescribed to adults with chronic heart failure to reduce the risk of hospitalization, while Sensipar is used to manage secondary hyperparathyroidism in patients with chronic kidney disease on dialysis.

According to the California State Board of Pharmacy, the affected products include:

• Corlanor 5 mg tablets (60-count and 14-count bottles)
• Corlanor 7.5 mg tablets (60-count bottles)
• Sensipar 30 mg, 60 mg, and 90 mg tablets (30-count bottles)

Reason for the Recall

The recall was triggered after “unexpected foreign matter” was identified on the exterior surface of tablets in a reserve sample from one specific lot. Critically, the foreign substance was found over the coating rather than embedded within the tablets themselves, suggesting a packaging or environmental contamination issue rather than a raw material problem.

“The unexpected foreign matter was localized on the exterior tablet surface, over the coating,” the California Board of Pharmacy stated in its recall alert. “Therefore, as a precautionary measure, all lots within expiry that were processed in AML Building 23 packaging area, where the condition occurred, are being recalled.”

An Amgen spokesperson told PEOPLE that the company initiated the recall as a precautionary measure, adding: “While Amgen has determined that the presence of the foreign matter represents a low potential health risk to patients, some tablets may not meet internal quality standards for appearance.”

Risk Assessment

Despite the scale of the recall, health authorities have emphasized that the risk to patients is low. The California Board of Pharmacy’s hazard assessment concluded that the “medical impact and physical hazard associated with the identified foreign material do not pose a clinical risk to patients, and the overall patient safety risk is low.”

The FDA’s Class II classification — a mid-level designation — indicates that exposure “may cause temporary or medically reversible adverse health consequences” but that “the probability of serious adverse health consequences is remote.” No complaints or adverse events related to the issue have been reported.

Broader Quality Control Concerns

The recall notice also cites deviations from Current Good Manufacturing Practice (CGMP) regulations, though the specific nature of those deviations has not been publicly detailed. CGMP standards are FDA-enforced requirements ensuring pharmaceutical products are consistently produced and controlled according to quality benchmarks.

This dual citation — foreign matter contamination alongside CGMP deviations — raises questions about quality assurance processes at Amgen’s AML Building 23 packaging facility. However, the lack of specific details about either the foreign substance or the exact nature of the manufacturing deviations makes it difficult to assess the severity of the underlying issues.

What Patients Should Know

Patients currently taking Corlanor or Sensipar are advised to check their medication bottles against the list of recalled lot numbers, which can be accessed through the FDA’s enforcement database. Healthcare providers and patients with questions can contact the FDA directly. Amgen’s stock (AMGN) showed minimal market reaction, trading at $358.33 with a slight increase of 1.56% on the day of the report, suggesting investors view the recall as a contained event.

Looking Ahead

While this recall appears to be a precautionary measure rather than a response to documented harm, it underscores the importance of rigorous quality control in pharmaceutical manufacturing. The incident leaves several open questions — including the precise identity of the foreign substance, the specific CGMP deviations involved, and whether the FDA will conduct further investigations into Amgen’s manufacturing practices. As the situation develops, patients and healthcare providers should monitor FDA announcements for updates.